ALX Oncology Holdings
Stock Forecast, Prediction & Price Target
ALX Oncology Holdings Financial Estimates
ALX Oncology Holdings Revenue Estimates
ALX Oncology Holdings EBITDA Estimates
ALX Oncology Holdings Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $625K Low: $625K High: $625K avg. 0% | Avg: $10.87M Low: $10.87M High: $10.87M avg. 1639.43% | Avg: $81.19M Low: $81.19M High: $81.19M avg. 646.87% | Avg: $239.28M Low: $239.28M High: $239.28M avg. 194.70% |
Net Income
% change YoY
| $-83.46M N/A | $-123.48M -47.94% | $-160.80M -30.22% | Avg: $-166.45M Low: $-143.57M High: $-91.56M avg. -3.51% | Avg: $-191.34M Low: $-157.33M High: $-80.38M avg. -14.95% | Avg: $-86.19M Low: $-86.19M High: $-86.19M avg. 54.95% | Avg: $-18.80M Low: $-18.80M High: $-18.80M avg. 78.17% |
EBITDA
% change YoY
| $-83.47M N/A | $-127.43M -52.67% | $-158.40M -24.30% | Avg: $124.99K Low: $124.99K High: $124.99K avg. 100.07% | Avg: $2.17M Low: $2.17M High: $2.17M avg. 1639.44% | Avg: $16.23M Low: $16.23M High: $16.23M avg. 646.87% | Avg: $47.85M Low: $47.85M High: $47.85M avg. 194.70% |
EPS
% change YoY
| -$2.07 N/A | -$3.03 -46.37% | -$3.74 -23.43% | Avg: -$2.88 Low: -$3.34 High: -$2.13 avg. 22.91% | Avg: -$2.8 Low: -$3.66 High: -$1.87 avg. 2.95% | Avg: -$2.01 Low: -$2.01 High: -$2.01 avg. 28.33% | Avg: -$0.44 Low: -$0.44 High: -$0.44 avg. 78.17% |
Operating Expenses
% change YoY
| $83.55M N/A | $127.43M 52.51% | $170.27M 33.61% | Avg: $2.02M Low: $2.02M High: $2.02M avg. -98.80% | Avg: $35.26M Low: $35.26M High: $35.26M avg. 1639.43% | Avg: $263.39M Low: $263.39M High: $263.39M avg. 646.87% | Avg: $776.23M Low: $776.23M High: $776.23M avg. 194.70% |
FAQ
What is ALX Oncology Holdings stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 28.66% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -143.57M, average is -166.45M and high is -91.56M.
What is ALX Oncology Holdings stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 620.25% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $625K, average is $625K and high is $625K.
What is ALX Oncology Holdings stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 33.09% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$3.34, average is -$2.88 and high is $-2.13.
What is the best performing analyst?
In the last twelve months analysts have been covering ALX Oncology Holdings stock. The most successful analyst is Colin Bristow.